Immutep Limited Share Price & Technical Analysis
IMMP · $0.49 (+2.08%)
Healthcare / Biotechnology
$0.49
+2.08%
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes …
Price chart
Seasonality
May has 4 positive and 0 negative years (last 5 years shown)
0% return in May, 14% avg return in past 3 year May month.
-67% return in 2026, 19% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -7% | 4% | -89% | 25% | 0% | – | – | – | – | – | – | – | -67% |
| 25 | -5% | -5% | -5% | -6% | 12% | -16% | 0% | -6% | 13% | 6% | 5% | 45% | 38% |
| 24 | -12% | 5% | -4% | 17% | 11% | -33% | 10% | 18% | -15% | -18% | 11% | 5% | -6% |
| 23 | 5% | -20% | 6% | -6% | 18% | 5% | 5% | -14% | 0% | 0% | 5% | 20% | 25% |
| 22 | -18% | -14% | 13% | -18% | 25% | -33% | 15% | -9% | -20% | 13% | 33% | -28% | -42% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$66.76M
P/E ratio
—
52W high
$3.53
52W low
$0.29
Volume
3,63,186
Beta
2.36
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Immutep Limited share price today?
- Immutep Limited (IMMP) last traded around $0.49 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IMMP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IMMP. Download the app for real-time alerts.
- How can I analyze Immutep Limited stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.